• Press Release

UK biotech sector enjoys record year of investment

A record £3 billion has been raised by the UK biotech and life science sector in the first three quarters of 2021, according to new data released today by the BioIndustry Association (BIA) and Clarivate. With £576m raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.

BIA launches Comprehensive Spending Review priorities to turn UK into a life sciences superpower

The BioIndustry Association (BIA) has today launched its recommendations for the Comprehensive Spending Review, the report ‘Becoming a life sciences superpower’, explains the policies that the Government can implement to turbo charge growth in the innovative UK biotech and life sciences sector.

New report reveals strength of the UK’s thriving genomics sector

The BioIndustry Association (BIA), the Wellcome Sanger Institute and Medicines Discovery Catapult (MDC) have today launched Genomics Nation, showcasing the strength, breadth and opportunity of the UK’s genomics sector for investors, patients and the UK economy.

New investors drawn to UK biotech as global appetite for innovation continues

New analysis shows that biotech shares on the London Stock Exchange continued to out-perform the wider market in the first half of 2021 as international investors were drawn to the UK’s strong science and high-quality companies.

BIA welcomes government’s new Life Sciences Sector Vision

The Life Sciences Sector Vision brings together the collective ambition of the Government and the sector for the UK to be the leading global location for the life sciences businesses to innovate, grow and deliver breakthroughs to patients and the public in all parts of the UK.

UK life sciences on the cusp of a golden age as £1.6 billion raised in just three months

New data from the BioIndustry Association (BIA) and Clarivate shows that the UK’s biotech and life sciences sector is on the cusp of a golden age driven by strong demand from global investors for UK innovation, with £1.56bn invested in the last quarter (March 2021 – May 2021). This is the highest total amount ever recorded for a quarter since the trade association began recording this data.

The public strongly agree that patients living with a rare disease should be able to equally access medicines on the NHS, new report reveals

The BIA has today launched a report Public attitudes to Rare Diseases: The case for equal access which presents the findings of a survey commissioned by the BIA on public attitudes towards rare diseases and access to medicine.

Instrumental figures in UK COVID-19 vaccine development recognised in Queen’s Birthday Honours 2021

The Queen’s Birthday Honours 2021 has been released with several UK biotech and life sciences figures receiving honours for their contributions to the UK’s response to the COVID-19 pandemic. Those receiving honours include: Kate Bingham, former Chair of the UK Vaccine Taskforce (VTF), has received a damehood Ian McCubbin, former Vaccine Manufacturing expert on the VTF, former VP of global supply for GSK and former chair of the BIA’s COVID-19 Vaccine Manufacturing Taskforce, has received a CBE Annette England (Netty), bioprocessing consultant for the BIA, has received an MBE

BIA reacts to publication of the 2021/22 Genome UK Implementation Plan

Steve Bates OBE, Chief Executive of the BIA said: "The UK has a long legacy in genomic research and the Government is right to build on our global competitive advantage by committing to a series of actions to begin to deliver on the ambitious vision set out in Genome UK. The UK is in a unique position globally to leverage our strong academic base and leadership in major initiatives such as the 100,000 Genomes Project to truly kick-start a world-leading genomics industry.

BIA welcomes fresh Biomedical Catalyst funding for UK biotech

The BIA has today welcomed the Government’s announcement that £18m will be invested in innovative UK life science companies through a relaunched Innovate UK Biomedical Catalyst competition.